Pulmonx CORP 10-Q quarterly reports

Pulmonx Corporation filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in revenue and a net loss, while also detailing debt financing and operational updates.

Pulmonx Corporation reported a decrease in revenue for the first quarter of 2026 compared to the prior year, primarily due to a lack of sales in China.

Pulmonx Corporation reports increased revenue in Q3 2025, driven by Zephyr Valve procedure volumes, but continues to incur significant net losses and negative cash flows from operations.

Pulmonx Corporation announced increased revenue for the second quarter and first half of 2025, driven by Zephyr Valve adoption, but reported continued net losses and a reliance on future funding to support ongoing operations and product development.

Pulmonx Corporation announces a 19.5% increase in revenue for the first quarter of 2025, driven by growth in both U.S. and international markets, while still reporting a net loss.

Pulmonx Corporation's third quarter 2024 results show a revenue increase of 15.4% year-over-year, but the company continues to operate at a net loss.

Pulmonx Corporation's second quarter 2024 results show a 20.9% increase in revenue compared to the same period last year, driven by growth in Zephyr Valve procedure volumes.

Pulmonx Corporation's first quarter of 2024 saw a 29.7% increase in revenue year-over-year, though the company continues to operate at a net loss.